or tumbler agitation. Measurement of pH, hypotonic shock response and serotonin uptake indicated in vitro viability was well maintained during 5-7 days storage using either type of pack with either mode of agitation. The longer storage interval did not effect either plasma fibrinogen concentrations or binding of monoclonal antibody, AN5 1. However, gross contamination of the units with leucocytes caused increased glucose consumption, substantial fall in pH and loss of in vitro viability after five days storage. The work suggests the shelf-life of platelet concentrates can be extended to five days and that they are clinically effective providing the leucocyte contamination is minimised.
The maximum shelf-life of platelet concentrates stored at 22°C is at present 72 h which, with the ever-increasing requirement for platelet concentrates, makes inventory control very difficult.' Previous studies have shown that it is essential to maintain physiological pH during in vitro storage of platelet concentrates.23 New formulation plastics are being developed which have superior permeability to oxygen and carbon dioxide relative to the currently available packs with the resultant better maintenance of pH. If successful the shelf-life of platelet concentrates may be increased. In the present study two Buffy coat was removed from the donation of whole blood, immediately after the platelet rich plasma had been expressed. Two units of A, 0 and Rh compatible buffy coat were pooled together in a 150 ml Transfer Pack (Fenwal 4R 2001) , selecting the same units as would be pooled for comparative platelet assessment. One volume 6% Dextran 150 saline (Fisons Ltd, Pharmaceutical Division) was added to 10 volumes of the buffy coat pool. The unit was allowed to sediment for one hour in a plasma expressor, after which time the leucocyte rich supernatant was removed with a 25 ml syringe and needle 16G via a medical injection site coupler (Fenwal 4C 2405). This supematant was added to one of the paired units of platelet rich plasma, the other unit of platelet rich plasma being given an equivalent amount of 6% Dextran only. Both units of platelet rich plasma were then processed as above. The final estimated concentration of Dextran 150 saline in the platelet concentrate was approximately 0-2%.
SAMPLING
Five ml samples of each platelet concentrate were removed aseptically using a sampling site coupler (Fenwal 4C 2405) under Laminar air flow at 0, 3, 5 and 7 days of storage.
IN VITRO ASSAYS
Determination of platelet and white blood cell counts and mean platelet volume (MPV) were carried out using a Coulter S plus (Coulter Electronics Ltd, Luton, Beds).
The pH, hypotonic shock response, serotonin uptake and adenosine-5-diphosphate (ADP)-induced aggregation studies were carried out as previously described5 with certain modifications to the HSR assay. Platelet concentrate was diluted 1 volume to 3 volumes platelet poor plasma prior to testing. The hypotonic shock response was subsequently measured at 2 min and 5 min intervals. Glucose estimations were carried out on a Beckman glucose Analyser 2 (Beckman RIIC Ltd), while the fibrinogen estimates were determined by Clot Weight Technique using the method of Ingrams" I as modified by Royal Free Hospital Haemophilia Centre.
Formaldehyde-treated platelets were prepared by a modification of the method described by Macfarlane et al."2 Platelet preparations were washed three times in 0-01 M Tris, 0-01 M EDTA, 0-15 M NaCl pH 7.5 (TES) by repeated centrifugation in an IEC Centra 7 centrifuge at 1500 g for 8 min. The platelets were then resuspended in TES pH 7-5 containing 1% formaldehyde. After incubation for at least 18 h at 4°C the platelets were washed three times with TES and resuspended in this buffer prior to storage at 4°C. The binding of monoclonal antibody AN5113 was assayed using a double antibody assay.'4 '25I-labelled sheep or rabbit anti-mouse F (ab)2 fragment (Amersham International Ltd) was diluted with unlabelled affinity purified rabbit anti-mouse IgG (prepared as described by Jensenius and Williams,'4 1-56 u Ci/ml; 98-4 ,ug protein/ml) and 6*9,ug protein was added to each test.
STATISTICS
Statistical analysis was carried out using Student's t test.
Results
The initial platelet counts of paired platelet concentrates prepared for storage in either the Cutter CLX or Travenol PL-732 platelet packs were 1400 ± 460 x 109/l (n = 11; Cutter CLX) and 1270 ± 350 x 109/l (n = 11; Travenol PL 732) and the count remained unchanged with storage up to seven days. These platelet concentrates were stored with either tumbler (n = 12) or horizontal (n = 10) mixing and comparison of these two methods of mixing for each type of platelet pack showed very similar results with storage for seven days. Thus the pH, hypotonic shock response and serotonin uptake are presented irrespective of the method of mixing (Table 1 ). An initial increase in pH was observed in some units stored in both types of packs at three days storage and the pH had declined by five days storage. The pH of the platelet concentrates was well maintained over seven days storage with a minimum pH of 6 5 observed when platelet concentrates were stored in Travenol packs whereas one of the units had a pH of 5-6 with storage in Cutter packs. There was no significant difference (p > 0-05) in the pH during storage in either type of pack.
Aggregation induced by ADP (100 ,uM) was carried out on a limited number of units. The level of aggregation declined with storage and some units gave no response after seven days storage.
Hypotonic shock response was very well maintained over seven days storage with no significant Plasma fibrinogen concentration did not alter significantly over the seven day storage interval, whether platelets were stored with buffy coat (n = 10) (day 0 = 2 2mg/ml + 0*1; day 7 = 2-6mg/ml + 0.6) or without buffy coat (n = 10) (day 0 = 2*5 mg/ml + 0-3; day 7 = 2*7 mg/ml ± 0.3).
The binding of a monoclonal antibody AN51 to formaldehyde-treated platelets was studied. There was no alteration in the level of binding to platelets stored in the absence of buffy coat, (n = 6) (day 7 = 100%). However, there was only marginal reduction in the level of binding when platelets were stored in the presence of buffy coat, (n = 6) (day 7 = 89-5%). 1384 Taylor and an increase of glucose consumption. Contamination of the platelet packs with low levels of erythrocytes or low levels of leucocytes appeared to have no effect on the glucose consumption, lactate production or fall in pH. '7 18 Although different plastics with superior gas exchange to that of PL-146 were used in this study, heavy leucocyte contamination resulted in increased glucose consumption and a substantial fall in pH even after three days storage. Clearly this fall in pH affected the in vitro viability of the platelets.
Plasma fibrinogen was not activated in the presence or absence of buffy coat suggesting the appearance of macroaggregates in packs with buffy coat and the corresponding fall in white cell count was due to aggregated white cell debris. Further investigations may indicate whether other plasma proteins may be affected.
AN51 binding studies using platelet concentrates stored for up to seven days in the absence of buffy coat suggest there was no detectable loss of GPIb during storage of these platelets. Similar findings were found for platelet concentrates stored for up to 72 h at 22°C in PL-146 packs.'9 However, storage in the presence of buffy coat may cause some reduction in the level of GPIb possibly as a result of proteolysis. 20 Although the activity of the platelet calcium-dependent protease may be inhibited by the presence of citrate, leucocytes are a very rich source of proteolytic enzymes. Proteolytic enzymes may be released from damaged leucocytes and cleave membrane glycoproteins and the presence of a chymotrypsin-like enzyme from human leucocytes has been demonstrated.2'
The small clinical study indicated that platelet concentrates stored in CLX or PL-732 for five days were effective in stopping active bleeding in two thrombocytopenic patients and that satisfactory increments in peripheral blood platelet counts could be demonstrated in six patients after the infusion of 12 units of platelets.
The in vitro studies have shown that approximately one in ten platelet preparations could be contaminated with leucocytes and therefore significantly reduce platelet viability. It is usual to transfuse adult patients with six units of platelets per day and there would therefore be a risk that every two or three days one unit may contain platelets of poor viability. However in paediatric practice young children may require less units of platelets each day and it would be most important to identify units where the viability of the platelets is suspect.
In conclusion, the pH and in vitro platelet viability were maintained with storage for up to seven days using either PL-732 or Cutter CLX packs. The work suggests it is essential to ensure very low levels of contaminating leucocytes are achieved as these can adversely affect the pH and glucose concentration and hence the viability of the platelets during in vitro storage..-As irreversible aggregation of leucocytes
